Michael Barbella, Managing Editor06.16.23
Accel Research Sites Network has long been dedicated to bringing innovative treatments to patients through cutting-edge clinical trials. The company will now be able to serve a larger population, expanding its community reach and driving healthcare forward everywhere.
The company has acquired two new site locations in Ormond Beach, Fla., and Edgewater, Fla. The sites—Ormond Medical Arts (OMA)-Pharmaceutical Research Center, formerly Complete Health Research—will now be known as Accel Research Sites Ormond Beach and Accel Research Sites Edgewater.
The two new sites will add to the network for a total of 25 sites across three states in the Southeast.
“Our mission and vision centers around patients, partners and people,” Accel Research Sites CEO Lora Parahovnik said. “We are thrilled the addition of these sites means we will be able to work with outstanding providers, deepen our team, and most importantly, reach even more patients in communities who can benefit from innovative treatment and research.”
The new sites have expertise in clinical trials for women’s health, migraine, dermatology, osteoarthritis, blood/specimen collections, pulmonology, diabetes, hypertension, and hyperlipidemia. Both sites have access to a local lab and two area imaging facilities for computed tomography, DEXA, mammogram, ultrasounds and X-rays. They also have capabilities for infusions at the Edgewater location.
The acquisition also means the addition of six experienced principal investigators to the Accel team, as well as clinical staff members to support operations.
Both sites are strategically placed in the greater Central Florida area close enough to be supported by Accel’s central functions, but still mean Accel will have the chance to serve expanded patient populations in Florida. The Edgewater site, particularly, is strategically placed to provide exciting treatment options to a community that might not otherwise have access.
The acquisition is the latest in Accel’s efforts to expand care. Over Parahovnik’s tenure, the company has tripled its locations, servicing an area of Florida across the I-4 corridor, as well as offering several locations in the Birmingham, Ala., and Atlanta, Ga., areas.
Accel Research Sites Network is a multi-therapeutic network of clinical research sites dedicated to the delivery of treatment options to patients and providers. The company partners with pharmaceutical, biotechnology, and medical device companies worldwide to advance healthcare and wellness.
The company has acquired two new site locations in Ormond Beach, Fla., and Edgewater, Fla. The sites—Ormond Medical Arts (OMA)-Pharmaceutical Research Center, formerly Complete Health Research—will now be known as Accel Research Sites Ormond Beach and Accel Research Sites Edgewater.
The two new sites will add to the network for a total of 25 sites across three states in the Southeast.
“Our mission and vision centers around patients, partners and people,” Accel Research Sites CEO Lora Parahovnik said. “We are thrilled the addition of these sites means we will be able to work with outstanding providers, deepen our team, and most importantly, reach even more patients in communities who can benefit from innovative treatment and research.”
The new sites have expertise in clinical trials for women’s health, migraine, dermatology, osteoarthritis, blood/specimen collections, pulmonology, diabetes, hypertension, and hyperlipidemia. Both sites have access to a local lab and two area imaging facilities for computed tomography, DEXA, mammogram, ultrasounds and X-rays. They also have capabilities for infusions at the Edgewater location.
The acquisition also means the addition of six experienced principal investigators to the Accel team, as well as clinical staff members to support operations.
Both sites are strategically placed in the greater Central Florida area close enough to be supported by Accel’s central functions, but still mean Accel will have the chance to serve expanded patient populations in Florida. The Edgewater site, particularly, is strategically placed to provide exciting treatment options to a community that might not otherwise have access.
The acquisition is the latest in Accel’s efforts to expand care. Over Parahovnik’s tenure, the company has tripled its locations, servicing an area of Florida across the I-4 corridor, as well as offering several locations in the Birmingham, Ala., and Atlanta, Ga., areas.
Accel Research Sites Network is a multi-therapeutic network of clinical research sites dedicated to the delivery of treatment options to patients and providers. The company partners with pharmaceutical, biotechnology, and medical device companies worldwide to advance healthcare and wellness.